195 related articles for article (PubMed ID: 22229848)
1. Predictors of response to targeted therapy in renal cell carcinoma.
Eisengart LJ; MacVicar GR; Yang XJ
Arch Pathol Lab Med; 2012 May; 136(5):490-5. PubMed ID: 22229848
[TBL] [Abstract][Full Text] [Related]
2. Sequential use of targeted agents in the treatment of renal cell carcinoma.
Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
[TBL] [Abstract][Full Text] [Related]
3. [Biomarkers of response to molecular targeted therapy in renal cell carcinoma].
Mizuno R; Oya M
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1088-91. PubMed ID: 21772092
[TBL] [Abstract][Full Text] [Related]
4. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
Sonpavde G; Choueiri TK; Escudier B; Ficarra V; Hutson TE; Mulders PF; Patard JJ; Rini BI; Staehler M; Sternberg CN; Stief CG
Eur Urol; 2012 Feb; 61(2):307-16. PubMed ID: 22055147
[TBL] [Abstract][Full Text] [Related]
5. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
Costa LJ; Drabkin HA
Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
[TBL] [Abstract][Full Text] [Related]
6. Precision medicine for metastatic renal cell carcinoma.
Sonpavde G; Choueiri TK
Urol Oncol; 2014 Jan; 32(1):5-15. PubMed ID: 24239472
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for renal cell cancer: current perspectives.
van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
[TBL] [Abstract][Full Text] [Related]
8. Resistance to targeted therapy in renal-cell carcinoma.
Rini BI; Atkins MB
Lancet Oncol; 2009 Oct; 10(10):992-1000. PubMed ID: 19796751
[TBL] [Abstract][Full Text] [Related]
9. Sequencing therapy in metastatic renal cell cancer.
Escudier B; Gore M
Semin Oncol; 2013 Aug; 40(4):465-71. PubMed ID: 23972710
[TBL] [Abstract][Full Text] [Related]
10. [Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis].
Johannsen M; Ringsdorf M; Römer A; Loening SA; Roigas J
Aktuelle Urol; 2007 Jan; 38(1):38-45. PubMed ID: 17290328
[TBL] [Abstract][Full Text] [Related]
11. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
12. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
Tang PA; Vickers MM; Heng DY
Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
[TBL] [Abstract][Full Text] [Related]
13. [Renal cell carcinoma-response criteria of molecular targeted therapy and the timing of sequential drugs in patients with advanced renal cell carcinoma].
Shinohara N
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1462-6. PubMed ID: 23064056
[TBL] [Abstract][Full Text] [Related]
14. Non-clear cell advanced kidney cancer: is there a gold standard?
Sánchez P; Calvo E; Durán I
Anticancer Drugs; 2011 Jan; 22 Suppl 1():S9-14. PubMed ID: 21173605
[TBL] [Abstract][Full Text] [Related]
15. Molecularly targeted agents for renal cell carcinoma: the next generation.
Cowey CL; Hutson TE
Clin Adv Hematol Oncol; 2010 May; 8(5):357-60, 361-4. PubMed ID: 20551895
[TBL] [Abstract][Full Text] [Related]
16. Optimizing treatment for metastatic renal cell carcinoma.
Patard JJ; Porta C; Wagstaff J; Gschwend JE
Expert Rev Anticancer Ther; 2011 Dec; 11(12):1901-11. PubMed ID: 22117157
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy for renal cell carcinoma: a new therapeutic paradigm.
Shaheen PE; Bukowski RM
Cancer Invest; 2006 Oct; 24(6):640-56. PubMed ID: 16982470
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Mulders P
BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
[TBL] [Abstract][Full Text] [Related]
19. New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies.
Tan TH; Pranavan G; Haxhimolla HZ; Yip D
Asia Pac J Clin Oncol; 2010 Mar; 6(1):5-18. PubMed ID: 20398033
[TBL] [Abstract][Full Text] [Related]
20. Management of metastatic renal cell carcinoma in the era of targeted therapies.
Webber K; Cooper A; Kleiven H; Yip D; Goldstein D
Intern Med J; 2011 Aug; 41(8):594-605. PubMed ID: 21627746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
